Screener / SEC EDGAR /CIK 0000885590 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Bausch Health Companies Inc. BHC

Compare with peers Embed
New in the 10-K 14 paragraphs with nothing like them in the 10-K filed Feb 20, 2025 New in the 10-Q 22 paragraphs not in the 10-Q filed Jul 30, 2026 10-Q against the 10-K 2 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 20, 2025. A box jumps to the paragraph as filed, below.

14 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

14 paragraphs in Risk Factors of the 10-K filed Feb 19, 2026 with nothing like them in the 10-K filed Feb 20, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

•our ability to manage the transition of key management positions and to recruit and retain executives and key personnel;

Read in the 10-K

•risks associated with the shifting geopolitical tensions between the U.S. and other members of the North Atlantic Treaty Organization (“NATO”);

Read in the 10-K

•our ability to adopt and integrate artificial intelligence solutions into various aspects of our business and operations responsibly and in compliance with applicable legislation, laws, rules, regulations and guidance;

Read in the 10-K

In addition, in the U.S., it has become increasingly common for patent infringement actions to prompt claims that antitrust laws have been violated during the prosecution of the patent or during litigation involving the defense of that patent.

Read in the 10-K

For certain of our products and manufacturing processes, we rely on trade secrets and other proprietary information, which we seek to protect, in part, through information technology systems discussed in more detail in the following section, and, in part, by confidentiality and nondisclosure agreements with our employees, consultants, advisors and partners. Trade secrets and proprietary information are difficult to protect. We also attempt to enter into agreements whereby such employees,

Read in the 10-K
Show the other 9

such transactions will occur, and a failure to complete such transactions could result in a negative perception by the market of us generally and a decline in the market price of our common shares.

Read in the 10-K

We are developing larsucosterol for the treatment of AH and potentially other conditions. The successful development of larsucosterol is subject to significant risks and uncertainties, including risks relating to the results and timing of clinical trials, the likelihood of future clinical trial results being positive with statistical significance and/or similar to results from previous trials, potential regulatory filings and approvals, and the potential benefits of Breakthrough Therapy Designation and Fast Track Designation. There can be no assurance that larsucosterol will receive regulatory approval or achieve commercial success, and any failure to successfully develop and commercialize larsucosterol could have a material adverse effect on our business.

Read in the 10-K

Some components and raw materials used in our manufactured products, and some finished products sold by us, are currently available only from one or a limited number of domestic or foreign suppliers. For example, with respect to some of our largest or most significant products, the supply of the finished product is only available from a single source (either one of

Read in the 10-K

Managed care organizations and other third-party payors try to negotiate the pricing of medical services and products to control their costs. Managed care organizations and pharmacy benefit managers typically develop formularies to reduce their

Read in the 10-K

In addition, the success of our fulfillment arrangements with Walgreen Co. and our dermatology cash-pay prescription program is subject to various risks, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, pharmacy benefit managers, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws. Any failure of these arrangements to achieve market acceptance or any non-compliance with applicable laws could have a material adverse effect on our business.

Read in the 10-K

▪tariffs imposed (or proposed to be imposed) by the U.S. (including in respect of the countries and sectors in which we do business) and counter-tariffs or other retaliatory measures imposed (or that may be imposed) on the U.S. by other countries, disruptions to global supply chains and the potential results of these developments;

Read in the 10-K

During 2025, the Trump administration imposed increased and new tariffs on various countries. Additional tariffs and other protective measures are being investigated and may also be imposed. Counter-tariffs and other retaliatory measures have been threatened and imposed on the United States by various countries. The United States has negotiated trade agreements with some countries on tariff matters and negotiations with others are ongoing. These tariffs and counter-tariffs have had and may continue to have an impact on some of the countries in and with which we do business and some of the sectors in which we are engaged. While we believe we will be able to mitigate some of the impact of these tariffs, counter-tariffs and other trade restrictions through the use of certain levers and other actions, these measures may not be successful in mitigating all of the impacts of these tariffs and other trade matters.

Read in the 10-K

Internationally, laws and regulations in many jurisdictions apply broadly to health-related and other sensitive and personal information, including the EU’s GDPR, and the UK’s General Data Protection Regulation (“UK GDPR”), which, together with national legislation, regulations and guidelines of the EU member states and the UK governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data, including health data from clinical trials and adverse event reporting. These laws and regulations could limit our ability to collect, use and share data, and could cause our compliance costs to increase, and ultimately could have an adverse impact on our business and financial condition.

Read in the 10-K

In recent years, shareholder activism involving corporate governance, fiduciary duties of directors and officers, strategic direction and operations has become increasingly prevalent.

Read in the 10-K

Paragraphs in the 10-Q filed Oct 29, 2026 that were not in the one before

New in the latest 10-Q

22 paragraphs in the 10-Q filed Oct 29, 2026 with nothing like them in the 10-Q filed Jul 30, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

On October 8, 2026, Bausch + Lomb entered into an agreement to acquire certain ophthalmic surgical manufacturing businesses. The acquisition is expected to close during the fourth quarter of 2026 for an upfront cash payment of approximately $ 85 million, due at closing.

Read in the 10-Q

During the third quarter of 2026, the Generics reporting unit revised its long-term forecast assumptions. As a result, the

Read in the 10-Q

Company performed an interim quantitative goodwill impairment assessment of the Generics reporting unit. Based on the quantitative assessment, the estimated fair value of the reporting unit exceeded its carrying value; therefore, no goodwill impairment charge was recognized.

Read in the 10-Q

During the three months ended September 30, 2026, Bausch + Lomb entered into a contract to sell a warehouse and equipment for an aggregate sale price of up to € 43 million, and then lease the assets back through a five-year leaseback transaction, with lease payments beginning in January 2028. As of September 30, 2026, Bausch + Lomb sold and leased back € 33 million of these assets. This transaction did not qualify as a sale under the applicable accounting guidance, and, as such, the associated warehouse and equipment remained included within Property, plant and equipment, net. Bausch + Lomb refers to failed sale-leasebacks as “other financial liabilities” and recorded the related obligations in Financial leases and Non-current portion of long-term debt in the Consolidated Balance Sheets.

Read in the 10-Q

common shares will be paid. Each vested PSU represents the right of a holder to receive a number of Bausch + Lomb’s common shares up to a specified maximum.

Read in the 10-Q
Show the other 17

Acquisition-related contingent consideration reflects changes in: (i) estimated amount and timing of projected cash flows of certain products and (ii) the timing of regulatory approval of certain pipeline products in 2025.

Read in the 10-Q

On July 26, 2023, a purported class action complaint captioned Kelk v. Bausch Health Companies Inc., et al. (No. 23-cv-03996), was filed in the U.S. District Court for the District of New Jersey against the Company and certain of its current

Read in the 10-Q

On September 22, 2026, the defendants filed motions to dismiss the antitrust complaints pending in the Rhode Island District Court that were filed in 2025.

Read in the 10-Q

On October 12, 2026, Thomas J. Appio was appointed Interim Chief Executive Officer of Bausch + Lomb. Mr. Appio will continue to serve as Chief Executive Officer of Bausch Health while assuming leadership of Bausch + Lomb. In connection with this appointment, Brent Saunders departed as Chief Executive Officer and as a member of the Board of Directors of Bausch + Lomb, effective October 12, 2026. Pursuant to a separation agreement, Mr. Saunders will receive a lump-sum cash payment of approximately $ 75 million. In addition, all of Mr. Saunders’ outstanding equity and equity-based awards in Bausch + Lomb were forfeited and cancelled.

Read in the 10-Q

On October 24, 2026, the Company’s Board of Directors authorized a share repurchase program pursuant to which the Company may repurchase up to $ 50 million of its outstanding common shares. The timing and amount of any repurchases will depend on market conditions and other factors, and the program does not obligate the Company to repurchase any particular amount of common shares and may be suspended or discontinued at any time.

Read in the 10-Q

Bausch + Lomb were transferred to 126NumberCo, which owns, in the aggregate, 211,963,893 common shares of Bausch + Lomb following such transfer.

Read in the 10-Q

On October 8, 2026, Bausch + Lomb entered into an agreement to acquire certain ophthalmic surgical manufacturing businesses. The acquisition is expected to close during the fourth quarter of 2026 for an upfront cash payment of approximately $85 million, due at closing.

Read in the 10-Q

Acquisition-related contingent consideration reflects changes in: (i) estimated amount and timing of projected cash flows of certain products and (ii) the timing of regulatory approval of certain pipeline products in 2025.

Read in the 10-Q

Acquisition-related contingent consideration reflects changes in: (i) estimated amount and timing of projected cash flows of certain products and (ii) the timing of regulatory approval of certain pipeline products in 2025.

Read in the 10-Q

Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025 Change in

Read in the 10-Q

• Acquisitions - On October 8, 2026, Bausch + Lomb entered into an agreement to acquire certain ophthalmic surgical manufacturing businesses. The acquisition is expected to close during the fourth quarter of 2026 for an upfront cash payment of approximately $85 million, due at closing; and

Read in the 10-Q

• On October 12, 2026, Brent Saunders, former Chief Executive Officer of Bausch + Lomb and a member of its Board of Directors, departed Bausch + Lomb pursuant to a mutual agreement with the Bausch + Lomb Board. Under the Separation Agreement entered into on October 11, 2026, Mr. Saunders will receive an aggregate lump-sum cash payment of approximately $75 million, payable in accordance with the agreement’s terms.

Read in the 10-Q

On October 24, 2026, the Company’s Board of Directors authorized a share repurchase program pursuant to which we may repurchase up to $50 million of our outstanding common shares. The timing and amount of any repurchases will depend on market conditions and other factors, and the program does not obligate us to repurchase any particular amount of common shares and may be suspended or discontinued at any time.

Read in the 10-Q

On October 28, 2026, the Company announced that its subsidiary, BHA will issue an irrevocable notice of redemption dated October 29, 2026 to redeem all of its outstanding 8.500% Senior Notes due 2027, representing approximately $643 million in aggregate principal amount and will be funded using cash on hand. The redemption is scheduled for November 30, 2026. In connection with the redemption, the indenture governing these notes will be terminated.

Read in the 10-Q

Risk Factors

Our chief executive officer also serves as interim chief executive officer and chairman of the board of directors of Bausch + Lomb, and these overlapping roles may create competing demands on management time and attention and actual or perceived conflicts of interest.

Read in the 10-Q

In October 2026, our chief executive officer, Thomas Appio, was appointed interim chief executive officer of Bausch + Lomb, effective October 12, 2026. In addition, in August 2026, Mr. Appio was appointed to the board of directors and as chairman of the board of directors of Bausch + Lomb. The overlapping roles at the Company and Bausch + Lomb may create competing demands on management time and attention. In addition, these overlapping roles may result in conflicts, or the appearance of conflicts, with respect to matters involving or affecting both companies. See Item 1A. “Risk Factors - In connection with any B+L Separation, some of our directors and officers may have actual or potential conflicts of interest because of their equity ownership in Bausch + Lomb, and/or because they also serve as officers or directors of Bausch + Lomb, which could impact our ability to grow our business or cause reputational or other harm” included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Read in the 10-Q

Share sales and buybacks

On October 24, 2026, the Company’s Board of Directors authorized a share repurchase program pursuant to which the Company may repurchase up to $50 million of its outstanding common shares. The timing and amount of any repurchases will depend on market conditions and other factors, and the program does not obligate the Company to repurchase any particular amount of common shares and may be suspended or discontinued at any time.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Oct 29, 2026 against Item 1A of the 10-K filed Feb 19, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:Except as set forth below, as of the date of this Form 10-Q, there have been no material changes to the risk factors as disclosed in Item 1A. “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Read in the 10-Q
Added10-Q Oct 29, 2026 vs 10-K Feb 19, 2026
Our chief executive officer also serves as interim chief executive officer and chairman of the board of directors of Bausch + Lomb, and these overlapping roles may create competing demands on management time and attention and actual or perceived conflicts of interest.

Read it in the 10-Q at sec.gov

Reworded10-Q Oct 29, 2026 vs 10-K Feb 19, 2026
“Risk Factors - In connection with any B+L Separation, some of our directors and officers may have actual or potential conflicts of interest because of their equity ownership in Bausch + Lomb, and/or because they also serve as officers or directors of Bausch + Lomb, which could impact our ability to grow our business or cause reputational or other harm. harm” included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Read it in the 10-Q at sec.govThe 10-K sentence

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 19, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 20, 2025

maintenance covenants ×6phase clinical ×4salix reporting ×4reporting unit ×4two global ×3generic rifaximin ×3retain executives ×2revolving credit ×2credit facility ×2subsidiary ltd ×2side arrangement ×2taxes imposed ×2xifaxan product ×2product line ×2rifaximin product ×2product earlier ×2
Where each one is used
  • maintenance covenants: The 2025 Credit Agreement and the various indentures governing our senior notes, including those issued in April 2025 and December 2025 by our subsidiary, 1261229 B.C. Ltd., contain covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take...
  • phase clinical: development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. In addition, the results of management reviews...
  • salix reporting: development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. In addition, the results of management reviews...
  • reporting unit: development programs may actually result in the commercialization of a product. We will not be able to commercialize our pipeline products if preclinical studies do not produce successful results or if clinical trials do not demonstrate safety and efficacy in humans. In addition, the results of management reviews...
  • two global: On October 8, 2021, the OECD published a statement that outlined the key components of a two-pillar plan to address the tax challenges arising from the digitalisation of the economy, agreed by the OECD/G20 inclusive framework on Base Erosion and Profit Shifting (the “Inclusive Framework”), which includes 145 member...
  • generic rifaximin: The development of new and innovative products, as well as protecting the underlying intellectual property of our product portfolio, is important to our success in all areas of our business. A significant number of the products we sell either: (i) have no meaningful exclusivity protection via patent or marketing or...
  • retain executives: •our ability to manage the transition of key management positions and to recruit and retain executives and key personnel;
  • revolving credit: We are unable to predict how long such proceedings will continue, but we anticipate that we will continue to incur significant costs in connection with some or all of these matters and that some or all of these proceedings will result in a substantial distraction of management’s time, regardless of the outcome....

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

28 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
Internationally, laws and regulations in many jurisdictions apply broadly to the collection, transmission, dissemination, use, privacy, confidentiality, security, retention, availability, integrity and other processing of health-related and other sensitive and personal information. For example, the EU’s GDPR, and the UK’s General Data Protection Regulation (“UK GDPR”), together with national legislation, regulations and guidelines of the EU member states and the UK governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze,...
In the 10-K filed Feb 20, 2025
In the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could impact our ability to sell our products profitably. The Patient Protection and Affordable Care Act, as amended by the Health Care Reform Act, may affect the operational results of companies in the pharmaceutical and medical device industries, including the Company and other health care related industries, by imposing on them additional costs. Effective January 1, 2010, the Health Care Reform Act increased the minimum Medicaid...
In the 10-K filed Feb 20, 2025
The withdrawal of the UK from the European Union (“Brexit”) also has created uncertainty with regard to the regulation of data protection in the UK. Since January 1, 2021, when the transitional period following Brexit expired, we have been required to comply with the GDPR as well as the UK GDPR (combining the GDPR and the UK’s Data Protection Act of 2018), which exposes us to two parallel regimes, each of which authorizes similar fines and may subject us to increased compliance risk based on differing, and potentially inconsistent or conflicting, interpretation and enforcement by...
In the 10-K filed Feb 20, 2025
defend against charges that we infringed, misappropriated or otherwise violated patents or the intellectual property or proprietary rights of third parties. Third parties may also request a preliminary or permanent injunction from a court of law to prevent us from marketing a product. Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. If we are found to infringe, misappropriate or otherwise violate the intellectual property rights of...
In the 10-K filed Feb 20, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BHC/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.